Regulations.gov document
Rare Diseases: Considerations for the Development of Drugs and Biological Products…
Other · FDA-2015-D-2818 · posted Dec 26, 2023
Key facts
| Document ID | FDA-2015-D-2818-0045 |
|---|---|
| Title | Rare Diseases: Considerations for the Development of Drugs and Biological Products; Guidance for Industry - Final Guidance |
| Document type | Other |
| Subtype | Guidance |
| Agency | FDA |
| Docket | FDA-2015-D-2818 |
| Posted | Dec 26, 2023 |
| Comment period opens | Dec 26, 2023 |
At a glance
- 10–99 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: